ArticleJournal of cancer research and clinical oncology2018

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.

Franco Trevisani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.